Introduction {#s1}
============

Although the cause of most Parkinson's disease remains unknown, autosomal dominant mutations in the leucine rich repeat kinase 2 (LRRK2) gene account for 1--2% of all cases (and 18% of cases in those of Ashkenazi Jewish descent) and lead to activation of the LRRK2 kinase ([@bib1]). Recent mass spectrometry efforts have revealed a subgroup of Rab GTPases as the primary substrates of LRRK2 ([@bib35]; [@bib36]). Rab GTPases are master regulators of all membrane trafficking events in eukaryotic cells ([@bib39]; [@bib27]). LRRK2 phosphorylation modifies the so-called switch 2 regions of Rab proteins that report the identity of the bound nucleotide. Because cognate effector and regulatory proteins interact with Rabs in a nucleotide-dependent manner via this motif, phosphorylation on the switch two loop interferes with the ability of Rabs to bind to most of their partner proteins ([@bib35]). Given the importance of the LRRK2 kinase in familial Parkinson's disease, there is great interest in determining which Rab-dependent processes are most significantly impacted by elevated LRRK2 kinase activity.

We recently showed that Rab29 GTPase, localized on the Golgi, recruits the predominantly cytoplasmic LRRK2 onto membranes and activates it's ability to phosphorylate downstream Rab8A and Rab10 substrates ([@bib28]; see also [@bib20]). Although Rab8A and Rab10 have distinct localizations and roles in different tissues, they (along with Rab29) have been implicated in the process of ciliogenesis. Primary cilia are single, microtubule-based cellular projections on many types of cells that are critical for developmental signaling via the Sonic hedgehog (Shh) pathway as well as for G-protein coupled receptor signaling pathways; they are produced in tight coordination with the cell cycle ([@bib14]; [@bib30]; [@bib43]; [@bib25]) showed that exogenous expression of Rab8A protein increased cilia length significantly, consistent with Rab8A being a limiting component of cilia formation. [@bib43] also discovered that the basal body associated, Cenexin-3 protein binds Rab8A and relocates to the primary cilium together with Rab8A upon serum starvation. Subsequent work has shown that both Rab8A and its guanine nucleotide exchange factor, Rabin8, are needed in part, for so-called BBSome function in ciliogenesis ([@bib25]; [@bib17]; [@bib42]; [@bib10]) and also for the delivery of membrane vesicles to the growing cilium ([@bib21]). Rab10 is detected in association with primary cilia in cultured MDCK and LLC-PK1 kidney cells and in rodent renal tubules ([@bib3]). Rab10 is also reported to be necessary for axonal membrane trafficking and axonal elongation ([@bib40]; [@bib19]).

We show here that Rab8A and Rab10 have opposing roles in normal ciliogenesis. Unlike Rab8A, Rab10 is a native suppressor of ciliogenesis, and upon LRRK2 phosphorylation, it binds preferentially to RILPL1 (Rab interacting lysosomal protein-like 1) protein to further interfere with cilia formation. These cilia modulatory events have important consequences in the brain where they influence the ability of cholinergic neurons to generate cilia in the somatosensory cortex; loss of cilia will decrease the ability of these neurons to respond to a Sonic hedgehog signal that triggers neuroprotective signaling toward dopaminergic circuits ([@bib12]).

Results {#s2}
=======

Rab8A increases while Rab10 inhibits cilia formation in A549 cells {#s2-1}
------------------------------------------------------------------

To explore the relationship between primary cilia and two important LRRK2 substrates, we revisited the contributions of Rab8A and Rab10 to primary cilia formation. Throughout the text, Rab8 will refer to Rab8A unless otherwise indicated. Consistent with previous reports ([@bib43]; [@bib25]; [@bib10]; [@bib17]; [@bib32]; [@bib3]), some of the total pool of Rab8A localized at the base and within primary cilia (detected with anti-Arl13b antibody; [Figure 1A](#fig1){ref-type="fig"}). In contrast, a portion of the total pool of Rab10 localized only to the base of cilia in both hTERT-RPE as well as primary, antibody-panned, rat astrocyte cells ([Figure 1A](#fig1){ref-type="fig"}). To study the roles of Rab8A and Rab10 in primary cilia formation, the proteins were knocked out of A549 cells using CRISPR-Cas9, and their depletions were confirmed by immunoblot ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). As shown previously, loss of Rab8A decreased significantly the capacity of A549 or RPE cells to generate primary cilia ([Figure 1B--D](#fig1){ref-type="fig"}). Surprisingly, loss of Rab10 increased the percentage of cells that made primary cilia compared with parental wild type A549 and RPE cells ([Figure 1B,C,E](#fig1){ref-type="fig"}). Importantly, the effects of Rab8A or Rab10 knockout on primary cilia formation were reversed upon re-expression of exogenous Rab8A or Rab10 wild type proteins ([Figure 1D,E](#fig1){ref-type="fig"}; Rab10,\~4 fold overexpressed and Rab8A,\~10 fold): exogenous Rab8A stimulated while Rab10 inhibited ciliogenesis in cells lacking these proteins. Note that RPE cells start at a higher level of intrinsic ciliation ([Figure 1C](#fig1){ref-type="fig"}, right) and thus there is less possibility of enhancing ciliation in this cell type.

![Rab10 is a negative regulator of primary cilia formation.\
hTERT-RPE cells ([Figure 1A](#fig1){ref-type="fig"}, upper panels) or primary rat astrocytes ([Figure 1A](#fig1){ref-type="fig"}, lower panels) were transfected with GFP-Rab8A (A, left) or GFP-Rab10 (A, right). 24 hr post transfection, cells were fixed and stained for primary cilia using anti-Arl13b antibodies (red). Dotted boxes indicate areas that are magnified in the insets. Yellow indicates co-localization between GFP-Rabs (green) and Arl13b (red). (**B**) A549 knock out cells lacking endogenous Rab10 (Rab10-KO) or Rab8A (Rab8-KO) were ciliated on glass coverslips and 48 hr later fixed and stained for primary cilia Arl13b (green). (**C**) Quantitation of data shown in (**B**) for A549 cells and also RPE cells analyzed in parallel. Error bars represent SEM from three experiments with \>200 cells per condition in each experiment. (**D,E**) Rab8A-KO or Rab10-KO A549 cells were infected with lentivirus to stably express wild type GFP-Rab8A or GFP-Rab10, respectively. Cells were ciliated on coverslips and stained for Arl13b. (**D**) Quantitation of primary cilia in Rab8A-KO A549 cells stably expressing GFP-Rab8A-WT. (**E**) Quantitation of primary cilia in Rab10-KO A549 cells stably expressing GFP-Rab10-WT. (**F**) Quantitation of primary cilia in Rab8A-KO A549 cells treated with Rab10 shRNA. (**G**) Quantitation of primary cilia in WT and Rab10-KO A549 cells expressing GFP-Rab8A. Error bars represent SEM from three experiments with \>200 cells per condition. \*, p\<0.05; \*\*, p\<0.01; \*\*\*. p\<0.001; ns = not significant. Scale bars = 10 µm.](elife-40202-fig1){#fig1}

Finally, to investigate the relationship between Rab8A ciliogenesis activation and Rab10 suppression, A549 cells lacking Rab8A were further depleted of Rab10 using a lentiviral shRNA. More than 90% of the endogenous Rab10 was depleted in these cells as seen by immunoblot ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, right panel). Surprisingly, loss of both Rab8A and Rab10 from A549 cells reversed the block of ciliogenesis observed in Rab8A KO cells ([Figure 1F](#fig1){ref-type="fig"}). Thus, Rab10 is a dominant suppressor of cilia formation. Even though A549 Rab10 KO cells are significantly ciliated, exogenous Rab8A even further increases ciliation in these cells ([Figure 1G](#fig1){ref-type="fig"}). Thus, Rab8A drives a Rab10-independent pathway for cilia formation. Note that loss of either Rab10 or Rab8A does not change the level of the other protein ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In addition, Rab8 goes to the cilium in Rab10KO cells, as in wild type cells.

Rab8A and Rab10 mutants cannot be used to mimic phosphorylation {#s2-2}
---------------------------------------------------------------

Phosphorylation of Rab proteins by LRRK2 has been shown to interfere with their ability of to bind to numerous, cognate effector proteins ([@bib35]). Studies of protein phosphorylation often utilize substrate mutants generated in the hope that they cannot be phosphorylated (T-to-A) or alternatively, that they will mimic the phosphorylation state (T-to-E). Unfortunately, we were unable to use such mutant Rab8A or Rab10 proteins as a series of functional and localization tests showed that they are nonfunctional. The non-phosphorylatable, threonine to alanine (TA) mutations in both Rab8A and Rab10 failed to reverse their respective ciliation phenotypes observed in knockout cells ([Table 1](#table1){ref-type="table"}), indicating that they are non-functional. Light microscopy of A549 cells expressing these mutants showed that unlike wild type Rab8A protein, Rab8A-TA was more concentrated over the Golgi and not seen in cilia; Rab8A-TE was more dispersed than the wild type protein and may aggregate upon expression in HEK293T cells. Rab10-TE was much more concentrated on the Golgi than the wild type protein and Rab10-TA was entirely cytosolic ([Figure 2A](#fig2){ref-type="fig"}), as confirmed by membrane fractionation after expression in HEK293T cells ([Figure 2B](#fig2){ref-type="fig"}). In vitro experiments using biotin-geranyl pyrophosphate as substrate confirmed that neither Rab8A-TE nor Rab10-TA mutants are good substrates for Rab geranylgeranyl transferase ([Figure 2C](#fig2){ref-type="fig"}). Finally, unlike the phosphorylated versions of Rab8A or Rab10 proteins ([@bib36]), Rab8A-TE and Rab10-TE failed to show enhanced interaction with GFP-RILPL1 protein ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This is a very important caution---the TA and TE mutants do not reflect the desired states and should not be used in future experiments exploring the consequences of Rab8A and Rab10 phosphorylation.

![Rab8A and Rab10 phospho-site mutants are non-functional proteins.\
(**A**) Rab8A-KO and Rab10-KO A549 cells were infected with lentivirus to stably express wild type (WT), phospho-mimetic (TE) or non-phosphorylatable (TA) mutants of Rab8A and Rab10, respectively. 24 hr post transfection, cells were fixed and stained with anti-GFP. (**B**) HEK293T cells were transfected with wild type (WT), T73E (TE) or T73A (TA) mutant GFP-Rab10 or GFP-Rab8A as indicated. After 24 hr, cells were fractionated into membrane and cytosol and 50 µg membranes and the equivalent volume of cytosol was immunoblotted using anti-GFP antibodies. Graph indicates the percent of total Rab10 or Rab8A protein that was membrane associated. (**C**) In vitro prenylation measured using cytosol fractions from (**B**), incubated for 4 hr with biotin-geranyl pyrophosphate at room temperature. The reaction was immunoprecipitated with GFP binding protein-Sepharose and samples were immunoblotted for biotin using Strepatavidin-Alexa 800 and anti-GFP.](elife-40202-fig2){#fig2}
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###### Summary of Rab8A and Rab10 phosphosite mutant protein properties

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rab protein   Membrane associated   Localization         In vitro prenylated   In/at base of cilia   Rescue ciliation in knockout cells   Bind RILPL1 strongly
  ------------- --------------------- -------------------- --------------------- --------------------- ------------------------------------ ----------------------
  Rab8A WT      YES                   Perinuclear Cilium   YES                   In/at base            YES                                  When phosphorylated

  Rab8A TA      YES                   Golgi                YES                   NO                    NO                                   NO

  Rab8A TE      Aggregated?           Golgi?               NO                    NO                    NO                                   POORLY

  Rab10 WT      YES                   Perinuclear\         YES                   At base               YES                                  When phosphorylated
                                      Cilium base                                                                                           

  Rab10 TA      NO                    Cytosol              NO                    NO                    NO                                   NO

  Rab10 TE      YES                   Golgi                YES                   NO                    NO\                                  POORLY
                                                                                                       (dominant effect)                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Phosphorylated Rab10 clusters near peri-centriolar membranes {#s2-3}
------------------------------------------------------------

Rab10 is phosphorylated in cells transfected with LRRK2 kinase ([@bib35]; [@bib28]). To identify the localization of both total and phospho-Rab10 (pRab10) by immuno-staining, HeLa cells were co-transfected with the activated, pathogenic mutant LRRK2-R1441G and GFP-Rab10. After 24 hr,\~80% of cells expressing exogenous LRRK2 showed total Rab10 concentrated over a perinuclear cluster ([Figure 3A,B](#fig3){ref-type="fig"}). Furthermore, labeling of LRRK2 expressing cells using a commercial anti-phosphoT73 Rab10-specific antibody revealed pRab10 staining only in LRRK2 co-expressing cells; the strongest pRab10 signal was also detected in the perinuclear region together with total Rab10 staining ([Figure 3C](#fig3){ref-type="fig"}). pRab10 localized adjacent to centrioles labeled with Centrin-3, and co-localized with perinuclear transferrin receptor (TfR)-containing membranes ([Figure 3C](#fig3){ref-type="fig"}). As noted earlier, RILPL1 interacts preferentially with the phosphorylated forms of Rab8A and Rab10 ([@bib36]); [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In HEK293T cells co-transfected with RILPL1-GFP and LRRK2, the clustered pRab10 co-localized perfectly with RILPL1 in the peri-centriolar region. This strong co-localization supports the conclusion that RILPL1 binds to pRab10 in cells.

![pRab10 localizes on peri-centriolar membranes.\
HeLa cells stably expressing GFP-Rab10 were transfected with or without LRRK2-R1441G plasmid. After 24 hr, cells were fixed and stained with the indicated antibodies. (**A**) Localization of total GFP-Rab10 (green) without (left) or with (right) R1441G-LRRK2 transfection. (**B**) Quantitation of peri-nuclear clustering of GFP-Rab10. (**C**) Cells were stained with rabbit anti-pRab10 antibody (red) and co-stained with either mouse anti-GFP (green), mouse anti-Centrin-3 (green) or mouse anti-transferrin receptor (TfR, green). (**D**) HEK293T cells were co-transfected with myc-LRRK2-R1441G and RILPL1-GFP (green). After 24 hr, cells were fixed and stained for pRab10 (red) and LRRK2 (blue). Dotted lines indicate cell boundaries. Dotted boxes indicate the enlarged region of interest. Scale bars, 10 µm.](elife-40202-fig3){#fig3}

RILPL1 regulates pRab10 localization {#s2-4}
------------------------------------

RILPL1 has been shown to associate with the mother centriole that becomes the basal body that nucleates the primary cilium ([@bib33]); RILPL1's C-terminal half is needed for this localization. We confirmed mother centriole localization of RILPL1 in A549 cells ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}); RILPL1-GFP co-localized with CEP164, a marker of the mother centriole. Previous work also indicated that RILPL1 influences the removal of signaling receptors from primary cilia ([@bib33]). Primary cilia form in G1 of the cell cycle and disassemble before mitosis. In RPE cells that had been induced to form cilia by serum starvation, endogenous RILPL1 co-localized with Rab10 at the base of primary cilia, identified by staining with anti-Arl13B antibodies ([Figure 4A](#fig4){ref-type="fig"}). A similar localization was also seen in ciliated, primary rat astrocytes ([Figure 4B](#fig4){ref-type="fig"}).

![Localization of pRab10 is influenced by RILPL1.\
(**A**) RPE cells were ciliated for 24 hr and stained with rabbit anti-RILPL1 antibodies (red) and co-stained with mouse anti-Arl13b or rabbit anti-Rab10 antibodies (green). (**B**) Rat primary astrocytes were ciliated and stained with anti-RILPL1 and anti-Arl13B antibodies as indicated. (**C--E**) HEK293T cells were infected with lentiviral shRNA for RILPL1 and selected by puromycin. LRRK2-R1441G was co-transfected with either RILPL1-WT. Also, RILPL1-C-terminus GFP or RILPL1-N-terminus GFP (green) were co-transfected with LRRK2 in wildtype cells. After 24 hr, cells were stained with anti-phospho-Rab10 antibody (red). (**D**) Quantitation of cells with peri-centriolar clustering of pRab10 in RILPL1 knock down HEK293T cells, with or without rescue by (full length) RILPL1-WT. (**E**) Quantitation of peri-centriolar clustering of pRab10 in cells transfected with full length, RILPL1-N terminus, RILPL1-C terminus. (**F**) A549 WT and A549-RILPL1 knock out cells were transfected with myc-LRRK2-R1441G and 24 hr later, stained with anti-pRab10 (red) and DAPI (blue). (**G**) Quantitation of total pRab10 in peri-centriolar clusters. (**H**) A549 WT and A549-RILPL1 knock out cells were lysed and analyzed by immunoblotting with the indicated antibodies. Error bars represent SEM from three experiments with \>50 cells per condition in each experiment. \*, p\<0.05; \*\*, p\<0.05; \*\*\*, p\<0.001. Scale bar, 10 µm.](elife-40202-fig4){#fig4}

When RILPL1 expression was decreased in HEK293T cells using a lentiviral shRNA, perinuclear clustering of pRab10 decreased and that phenotype was corrected upon RILPL1-GFP expression ([Figure 4D](#fig4){ref-type="fig"}). Indeed, perinuclear pRab10 clustering increased upon exogenous RILPL1 expression ([Figure 4D](#fig4){ref-type="fig"}). Overexpression of the C-terminal half of RILPL1 (RILPL1-C-GFP) dispersed pRab10 localization, whereas expression of the N-terminal half (RILPL1-N-GFP) had the same effect as the full length protein ([Figure 4C,E](#fig4){ref-type="fig"}). Previous work showed that overexpression of the RILPL1 C-terminal half interferes with RILPL1 localization and this region localizes RILPL1 to the centriole and dominantly blocks primary cilia formation ([@bib33]). Altogether, these data suggest that the RILPL1 N-terminus interacts with pRab10 in pericentriolar membranes; overexpression of the C-terminus dominantly interferes with cilia formation, perhaps by competing for interactions that localize pRab10 and RILPL1 to that cellular compartment. Nevertheless, even in the absence of RILPL1, some pRab10 localized to the pericentriolar region. This may be due to association with the related RILPL2 protein still present in these cells and/or to other proteins.

Similar results were obtained for pRab10 localization in A549 RILPL1 KO cells (created using CRISPR-Cas9; protein loss was confirmed by immunoblot; [Figure 4H](#fig4){ref-type="fig"}). While LRRK2 transfected, parental A549 cells displayed most pRab10 in a peri-nuclear cluster, RILPL1 KO A549 cells had a less focused distribution of pRab10 and showed additional punctate structures in the cytosol ([Figure 4F--H](#fig4){ref-type="fig"}). These data support the conclusion that RILPL1 enhances pRab10 clustering on pericentriolar membranes.

RILPL1 suppresses cilia formation at the mother centriole {#s2-5}
---------------------------------------------------------

Knockout of RILPL1 in A549 cells increased the percentage of cells that contained primary cilia, and the length of the cilia also increased ([Figure 5A,B](#fig5){ref-type="fig"}). This effect was abrogated upon expression of exogenous RILPL1 ([Figure 5C](#fig5){ref-type="fig"}), indicating that exogenous RILPL1 suppresses primary cilia formation, in wild type cells and in cells lacking RILPL1 protein. A similar inhibition of ciliogenesis was also detected in RPE cells ([Figure 5D](#fig5){ref-type="fig"}). Quantitation of ciliation as a function of RILPL1 expression in RPE cells showed that the phenotype was strongest in cells showing the highest RILPL1 expression levels ([Figure 5E](#fig5){ref-type="fig"}).

![RILPL1 is a negative regulator of ciliation.\
(**A**) Quantitation of primary cilia in WT and RILPL1-KO A549 cells. (**B**) Quantitation of cilia length in WT and RILPL1-KO cells. (**C**) Quantitation of cells with cilia when RILPL1-GFP is expressed in WT or RILP1-KO ad A549 cells. (**D**) Quantitation of cells with cilia when RILPL1-GFP is expressed in WT hTERT-RPE cells. (**E**) Quantitation of RILPL1-GFP expression in ciliated versus non-ciliated cells RPE by determining GFP signal intensity per cell in microscopy images. (**F**) Quantitation of cilia in A549 RILPL1-KO cells that were either un-transfected or transfected with GFP alone, GFP-Rab10 or GFP-Rab8A. (**G**) Quantitation of cilia in A549 cells lacking Rab8A or Rab10 as indicated, with or without RILPL1-GFP expression.](elife-40202-fig5){#fig5}

To further study how RILPL1, Rab10 and/or RILPL1/pRab10 complexes suppress ciliogenesis, GFP-Rab10 or GFP-Rab8A were expressed in A549 cells lacking RILPL1. In this background, exogenous Rab10 inhibited and Rab8A stimulated ciliogenesis, even in the absence of RILPL1 ([Figure 5F](#fig5){ref-type="fig"}). This suggests that Rab8A and Rab10 do not absolutely require RILPL1 for their effects on ciliogenesis or can mediate their effects via another protein such as the related RILPL2. In contrast, when exogenous RILPL1 was introduced into cells lacking Rab8A or Rab10, it was no longer capable of repressing ciliogenesis ([Figure 5G](#fig5){ref-type="fig"}). These experiments demonstrate that RILPL1 needs Rab10 to repress ciliogenesis, however, exogenous Rab10 can also suppress ciliogenesis independent of RILPL1 protein ([Figure 5D,E](#fig5){ref-type="fig"}). Because cells lacking Rab8A are already poorly ciliated, we cannot discern further RILPL1-inhibition in this cell background.

It was recently reported that LRRK2 overexpression in HEK293T cells decreases centrosomal cohesion ([@bib22]). Since RILPL1 and pRab10 accumulate in the pericentriolar region, we examined the effect of exogenous RILPL1 on centriolar markers in A549 cells ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). As noted earlier, exogenous RILPL1 was cytosolic but also enriched at the mother centriole ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Its expression was sufficient to trigger an increase in the distance between mother and daughter centrioles in some cells: specifically, 20% of A549 cells showed centrioles \> 2 µm apart, whereas 48% of cells showed this phenotype upon RILPL1 expression. However, there was no relationship between RILPL1 expression level and centriolar distance over 3 logs of expression measured by quantitative light microscopy ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This indicates that centriolar separation may be a secondary phenomenon, indirectly triggered in some cells by RILPL1 expression. No change in centriolar distance was detected in RILPL1 KO cells; finally, the ability of RILPL1 to increase centriole distance was completely nullified in Rab10 or Rab8A-KO cells while the RILPL1 localization remained unchanged. In summary, RILPL1 blocks ciliation by a Rab10-dependent process and may disrupts centriolar pairs in some cells under the same conditions.

LRRK2 kinase acts via a pRab10-RILPL1 pathway to inhibit ciliogenesis {#s2-6}
---------------------------------------------------------------------

We previously reported that mouse embryonic fibroblasts (MEFs) derived from LRRK2-R1441G mice showed fewer primary cilia, a phenotype that was reversed by adding the LRRK2-specific inhibitor, MLi2 ([@bib36]). Endogenous pRab10 was detected (for the first time) in R1441G LRRK2 MEF cells localized at the base of primary cilia ([Figure 6A](#fig6){ref-type="fig"}). The pRab10 staining was lost on treatment with MLi2 along with a concomitant increase in ciliogenesis ([Figure 6A,C](#fig6){ref-type="fig"}). Thus, LRRK2 phosphorylated Rab10 is seen concentrated at the base of primary cilia.

![LRRK2-mediated cilia defects require Rab10 and RILPL1.\
Rab10 and RILPL1 were depleted from LRRK2 R1441G MEFs using lentiviral delivery of shRNA. Cells were plated on coverslips or lysed for qPCR analysis 4 days post-infection. After 48 additional hours, cells were serum starved for 16 hr in the presence of 200 nM MLi2 or DMSO as indicated. (**A**) Cilia were stained with anti-Arl13b antibodies (red) and either anti-pRab10 (green) or anti-RILPL1 (green) as indicated. Nuclei were stained with DAPI (blue). Scale bar, 10 µm. Inset boxes show magnified regions including the cilium and its base. (**B**) Relative mRNA expression for Rab10 and RILPL1 in Rab10KD and RILPL1KD normalized to control R1441G-MEF cells. Error bars indicate standard error of the mean from quadruple qPCR replicates. (**C**) Quantitation of primary cilia in (left) R1441G-MEF cells or (right-most three bars) WT MEF cells,±MLi2,±Rab10 knock down or ±RILPL1 knock down. Error bars represent SEM from duplicate experiments quantifying \>100 cells per experiment. Student unpaired 2-tailed T-test values showing \*,\<0.05, \*\*,\<0.001. (**D**) Graphical representation of the working model in which RILPL1 and phosphorylated Rab10 suppressing cilia formation cooperatively. RILPL1 cannot inhibit ciliation in cells lacking Rab10; overexpression of Rab10 inhibits ciliation, and LKKR2 kinase increases the susceptibility of cells to RILPL1 inhibition by increasing the affinity of RILPL1 for p-Rab10 protein. Under these conditions, pRab8A can also bind RILPL1 and both Rab8A and Rab10 fail to bind most of their other effector proteins.](elife-40202-fig6){#fig6}

To investigate whether pRab10 and RILPL1 contribute to the defect in ciliogenesis observed in R1441G MEF cells, both proteins were depleted using lentiviral shRNAs. qPCR analysis showed more than 85% reduction in the levels of both mRNAs upon shRNA expression ([Figure 6B](#fig6){ref-type="fig"}). In control cells, RILPL1 and pRab10 localized to the base of cilia and this staining was lost upon expression of either of the corresponding shRNAs ([Figure 6A](#fig6){ref-type="fig"}). Importantly, when either Rab10 or RILPL1 was depleted, the effect of LRRK2 activity on cilia formation was completely abolished. These data demonstrate that the ability of pathogenic LRRK2-R1441G to influence cilia formation depends entirely on the presence of Rab10 and RILPL1 proteins.

[Figure 6D](#fig6){ref-type="fig"} compares two scenarios by which Rab10 and RILPL1 interfere with cilia formation. At endogenous levels of expression, we propose that pathogenic LRRK2 generates an inhibitory complex that contains pRab10 and RILPL1. RILPL1 shows enhanced binding to p-Rab10, and our data show that LRRK2 inhibition requires both of these proteins to yield a ciliation defect. In addition, in the absence of pathogenic LRRK2, upon overexpression of RILPL1, we also detect inhibition of cilia formation; this inhibition requires the presence of Rab10, and may reflect a similar inhibitor complex that requires overexpression to generate in the absence of Rab10 phosphorylation. In addition, overexpressed Rab10 can also inhibit cilia formation in a RILPL1-independent manner that may involve RILPL2 or other proteins; RILPL1 appears a more potent inhibitor than Rab10 upon overexpression. Further work is needed to explore this possibility. In summary, our data support a model in which pathogenic LRRK2 alters cilia formation by phosphorylating Rab10, which recruits RILPL1 to coordinately interfere with cilia formation ([Figure 6D](#fig6){ref-type="fig"}, right). In the absence of LRRK2 activation, exogenous RILPL1 can also block ciliation from its location adjacent to the mother centriole; in this scenario, RILPL1 requires Rab10 protein ([Figure 6D](#fig6){ref-type="fig"}, left). We speculate that additional copies of exogenous RILPL1 are sufficient to bind non-phosphorylated Rab10 protein to generate a dominant inhibitor of ciliation.

Pathogenic LRRK2 decreases sonic hedgehog signaling in MEFs and human iPS cells {#s2-7}
-------------------------------------------------------------------------------

How might cilia dysfunction influence Parkinson's disease pathology? Efficient Sonic hedgehog (Shh) signaling requires the ability of many cell types to form primary cilia and traffic signaling proteins such as Smoothened into the primary cilium ([@bib30]; [@bib7]). Shh signaling triggers a downstream pathway that increases the expression of the Gli1 transcription factor ([@bib8]; [@bib26]). To test whether LRRK2 interference with ciliogenesis alters the ability of cells to respond to Shh, R1441G-expressing MEF cells were treated with Shh, with or without the LRRK2 inhibitor, MLi2; the amount of Gli1 transcript produced was then monitored by qPCR. As shown in [Figure 7A](#fig7){ref-type="fig"}, Gli1 expression increased upon addition of Shh; moreover, inhibition of the LRRK2 kinase in these cells resulted in an almost two fold increase in the response of these cells to Shh. These experiments show clearly that the ability of LRRK2 to block cilia formation correlates directly with the ability of LRRK2 expressing cells to carry out Shh signal transduction.

![Ciliary signaling defects in MEFs and patient-derived iPS cells.\
(**A**) Confluent LRRK2 R1441G MEF cells were treated with 25 nM Sonic hedgehog (Shh) or PBS along with 200 nM MLi2 or DMSO for 24 hr under serum starvation conditions and then lysed for RNA isolation. Shown is the Gli1 mRNA level relative to GAPDH mRNA, normalized to control samples treated with both MLi2 and Shh. Error bars indicate standard error of the mean from three independent experiments. (**B--E**) Undifferentiated, patient derived LRRK2^G2019S/WT^ iPS cells were cultured for 48 hr on matrigel coated coverslips. They were fixed and stained for Arl13b (**B**) or lysed for RNA isolation and qPCR analysis (**E**). (**B**) Arl13b (green) and DAPI (blue) staining in G2019S or wild type cells as indicated. (**C,D**) Quantitation of ciliation and cilia lengths for LRRK2^WT/WT^ and LRRK2^G2019S/WT^ iPS cells; MLi2 treatment was for 24 hr (400 nM). (**E**) Relative mRNA expression of human Gli1 in LRRK2^G2019S/WT^ iPS cells normalized to LRRK2^WT/WT^ corrected cells as indicated. Error bars indicate SEM from two independent experiments, each done in duplicate. P values were from Student's unpaired 2-tailed t test; ns = not significant, \*\*,\<0.01, \*\*\*\*,\<0.001.](elife-40202-fig7){#fig7}

Similar results were obtained using patient-derived, induced pluripotent stem cells (iPS cells) carrying the LRRK2 G2019S mutation ([Figure 7B--E](#fig7){ref-type="fig"}). Undifferentiated LRRK2 G2019S iPS cells (LRRK2^G2019S/WT^), and the corresponding, zinc finger-corrected wild type cell line (LRRK2^WT/WT^; [@bib31]) were plated on matrigel-coated coverslips and stained for the presence of cilia after 72 hr. Cells carrying the G2019S mutation showed 50% less ciliation than the corresponding, corrected iPS cells; the length of the cilia were comparable ([Figure 7B,D](#fig7){ref-type="fig"}). Importantly, the extent of ciliation in the G2019S iPS cells was fully restored upon treatment with MLi2 ([Figure 7C](#fig7){ref-type="fig"}). Like their R1441G LRRK2 MEF cell counterparts, LRRK2^G2019S/WT^ iPS cells showed 50% less Gli1 expression than wild type cells, and this reduction was directly proportional to the extent of their loss of cilia ([Figure 7C,E](#fig7){ref-type="fig"}). These experiments demonstrate that pathogenic LRRK2 proteins can influence Shh signaling by changing the extent of ciliation in multiple cell types. That a heterozygous LRRK2 mutant iPS cell line showed this defect was striking.

LRRK2 R1441C mice show cilia defects in the brain {#s2-8}
-------------------------------------------------

To study further whether primary cilia defects seen in cell culture are also present in the brain, brain sections from 7 month old, LRRK2 R1441C mutant mice were compared with age- and litter-matched wild type animals. Sagittally sectioned brain slices were stained with neuron-specific primary cilia markers: adenylate cyclase 3 (AC3), the major neuron-specific primary cilia marker, and somatostatin receptor 3 (SSTR3) that is also found in primary cilia in certain brain regions ([@bib13]; [@bib5]; [@bib4]). According to the human protein atlas and ([@bib23]; [@bib41]), LRRK2 expression is highest in the cerebellum, hippocampus and cortex ([Figure 8G](#fig8){ref-type="fig"}). The majority of the neurons in the cortex, striatum and hippocampus (but not the cerebellum) had AC3^+^ primary cilia. SSTR3^+^ cilia were found in the cortex and the hippocampus but not in the striatum, presumably because striatal neurons themselves secrete somatostatin to signal to other cells.

![Primary cilia in mouse brain.\
Brains from wild type and 7 month old R1441C LRRK2 mice were stained with rabbit antibodies to neuron-specific primary cilia markers: somatostatin receptor 3 (SSTR3) or adenylate cyclase 3 (AC3). Primary cilia were quantified from somatosensory cortex, hippocampus and striatal regions. (**A**) Quantitation of neurons with SSTR3^+^ primary cilia in the cortex. (**B**) Percent of total neurons with AC3^+^ primary cilia in the cortex. (**C**) Representative image showing neuronal primary cilia stained for AC3 (red) and nuclei (blue) in the cortex. (**D**) Average length of primary cilia in the cortex (µm). (**E**) Cholinergic neurons in the striatum stained with goat anti-ChAT (choline acetyltransferase antibody, green), anti-AC3 (red) and nuclei (blue). (**F**) Quantitation of ChAT^+^ and ChAT^-^ neurons in the striatum with AC3^+^ primary cilia;\>50 cholinergic neurons were counted. (**G**) Cartoon depicting the regions in sagittal sections of mouse brains (yellow) where neurons were sampled for primary cilia (left image). Right panel depicts reciprocal communication between ChAT +neurons in the striatum (green) with tyrosine hydroxylase positive (TH+) dopaminergic neurons (grey) linked via Glia derived neurotrophic factor (GDNF) and Sonic hedgehog (Shh) signaling. Error bars represent standard error of the mean from n = 4 mice,\>500 cells per mouse; p values were determined by Student's unpaired 2-tailed t-test.](elife-40202-fig8){#fig8}

Primary cilia length and density varied between these brain regions. Consistent with data from MEF-R1441G and human iPS cells, fewer neurons in the somatosensory cortex of R1441C mouse brains had primary cilia compared to wild type brains, detected using anti-SSTR3 and AC3 antibodies ([Figure 8A,B](#fig8){ref-type="fig"}). No significant difference was found between R1441C and wild type neurons in terms of overall cilia lengths in the cortex, hippocampus or striatum ([Figure 8D](#fig8){ref-type="fig"}). Cilia densities were slightly lower in R1441C hippocampus but the differences were not statistically significant ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

Choline acetyl transferase (ChAT)-positive cholinergic neurons represent 1--4% of all neurons in the striatum ([@bib18]). These cholinergic neurons send long-distance projections onto tyrosine hydroxylase positive, dopaminergic neurons and also receive signals from them ([@bib37]; [@bib9]). Dopaminergic neurons send Shh signals to nearby striatal, cholinergic neurons that in return, send neuroprotective signals back to the dopaminergic neurons ([@bib12]). In the striatum, the overall ciliation of neurons was not significantly different in R1441C mice compared with wild type brains ([Figure 8F](#fig8){ref-type="fig"}). Importantly, when primary cilia were specifically monitored for ChAT-positive neurons, there was a striking reduction in the number of ciliated cholinergic neurons in R1441C striatum compared to wild type striatum ([Figure 8E,F](#fig8){ref-type="fig"}). R1441C mice had a highly significant cilia defect in cholinergic neurons that was not seen in wild type mice brains. These data suggest that loss of dopaminergic neurons in LRRK2-mediated Parkinson's disease may be a result of defective ciliogenesis in striatal cholinergic neurons, thus impairing a critical protective loop involving non-cell autonomous Shh signaling between cholinergic and dopaminergic neurons.

Discussion {#s3}
==========

We have shown here that Rab8A and Rab10 have opposite effects on ciliogenesis in multiple cell types: Rab8A stimulates cilia formation, while Rab10 inhibits this process. Rab8A and Rab10 share numerous effector proteins, and their phosphorylation by pathogenic LRRK2 kinase interferes with the ability of most of these effectors to interact with the Rabs. However, a few effector proteins, including RILPL1, bind Rab8A and Rab10 with preference for their phosphorylated forms ([@bib36]). This unusual class of effectors gains special focus in efforts to understand the downstream, physiological consequences of hyperactivated LRRK2 kinase that underlies familial Parkinson's disease.

We have shown here that pRab10 colocalizes with its RILPL1 effector on pericentriolar membranes adjacent to mother centrioles, and like Rab10, exogenous RILPL1 expression interferes with cilia formation. RILPL1 expression leads to more concentrated localization of pRab10 at centrosomes, consistent with the interaction of these proteins in cells. All of the above mentioned experiments involve exogenous expression of proteins that each may titrate out key players needed for cilia formation. Importantly, under conditions of *endogenous* protein expression, pathogenic LRRK2 kinase interferes with ciliation by generating pRab10 that binds endogenous RILPL1 and blocks cilia formation ([Figure 6D](#fig6){ref-type="fig"}). Moreover, LRRK2-mediated ciliation defects were not seen in cells lacking Rab10 or RILPL1, highlighting the importance of this pathway and these proteins in pathogenic LRRK2 signaling. How complexes of pRab10 block cilia formation together with RILPL1 protein will be important to elucidate in the future.

[@bib32] showed previously that mice lacking Rab8A and Rab8B show normal primary cilia formation; these mice die, however due to microvillus atrophy caused by failure to correctly generate these intestinal, apical membranes. Additional knockdown of Rab10 in double-knockout MEF cells reduced the percentage of ciliated cells in that study. It is important to note Rab8B still present in our cells may explain the differences in ciliation phenotypes that we have reported here.

How does altering ciliogenesis relate to Parkinson's disease pathology? Parkinson's disease is associated with loss of dopaminergic neurons in the brain. Little is known about primary cilia in the adult brain; both neurons and astrocytes are ciliated, and they contain typical signaling molecules that include AC3, SSTR and the Smoothened protein that is important for Shh signaling. We found, for the first time, that cholinergic neurons in the striatum show cilia defects in R1441C LRRK2 mutant mice; defects were also seen in the somatosensory cortex, marked by either SSTR or AC3. Kottman and coworkers ([@bib12]) have described a neuroprotective circuit in which Shh increases the resilience of dopaminergic neurons to toxins that mimic Parkinson's disease-associated, dopaminergic neuron loss. Cholinergic neurons of the striatum receive a Shh signal from dopaminergic neurons, which triggers secretion of dopaminotrophic, neuroprotective GDNF. Our data support a model in which pathogenic LRRK2 in cholinergic neurons impairs their ability to generate cilia, thereby blocking their receipt of the Shh signal from dopaminergic neurons. This pathway may be critical for the protection of dopaminergic neurons in aging brains, and represents a mechanism to explain the selective loss of dopamine neurons associated with the presentation of Parkinson's disease.

We cannot yet comment on the status of astrocyte cilia in LRRK2 mutant mice. Anti-AC3 antibodies rarely label astrocytes after postnatal day 10, and Arl13b has been used previously as an astrocyte cilia marker ([@bib16]). In our hands, mouse anti-Arl13b antibodies labeled cell bodies and processes of GFAP-positive and negative glial cells but failed to label primary cilia specifically. A possible explanation is that astrocyte cilia are four times shorter than neuronal cilia in rodent brains and they are deeply recessed into a ciliary pocket, perhaps making them harder to label and/or detect ([@bib6]). Additional work will be needed to assess the consequences of pathogenic LRRK2 on astrocyte ciliiogenesis throughout the brain.

Finally, it is important to note that LRRK2-mediated familial Parkinson's disease is quite distinct from more classic diseases of ciliogenesis called ciliopathies ([@bib29]). Patients carrying mutations in genes critical for cilia formation suffer diverse phenotypes including polycystic kidney disease, retinal degeneration, obesity, skeletal malformations and brain anomalies. Many of these symptoms are due to critical, developmental defects in Hedgehog and Wnt signaling processes that require ciliary pathways for proper signal transduction, even before birth. Because LRRK2 modulates Rab GTPase activity rather than permanently inactivating it, many cell types may have normal cilia formation or shorter cilia with decreased but still functional signaling capacity. It will be important to determine which cells and tissues display the greatest cilia defects in LRRK2 models of Parkinson's disease, and try to understand how those changes lead to specific loss of dopaminergic neurons in the brain.

In summary, pathogenic LRRK2 has a profound effect on cilia in cultured cells, and shown here, in human iPS cells and mutant mouse brains. Loss of ciliation correlates directly with loss of Shh signal reception in the striatum; other signaling events may also by altered. Olfactory receptor signals require cilia, and anosmia (loss of smell) is one of the earliest symptoms of Parkinson's disease. Future characterization of brain cilia in specific neuronal subtypes will provide critical information regarding pathways that may be altered in cells expressing pathogenic LRRK2; moreover, ciliation should be evaluated in cells from patients with idiopathic Parkinson's disease. Finally, Rab10 expression levels were reported as significantly increased in Alzheimer's disease brain ([@bib2]), suggesting that Rab10's role as a ciliogenesis inhibitor may also be relevant to Alzheimer's disease pathology.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation            Source or\                               Identifiers          Additional\
  (species)\                                          reference                                                     information
  or resource                                                                                                       
  ---------------------------- ---------------------- ---------------------------------------- -------------------- -------------
  Gene\                        RILPL1                 PMID: 29125462                                                
  (*Homo sapiens*)\                                                                                                 

  Gene\                        LRRK2                  PMID: 2912546\                           NM_198578.3          
  (*Homo sapiens*)                                    PMID: 29125462                                                

  Gene\                        Rab8a                  PMID: 29125462                                                
  (*Homo sapiens*)                                                                                                  

  Gene\                        Rab10Rab10             PMID: 29125462                                                
  (*Homo sapiens*)                                                                                                  

  Strain, strain\              B6.Cg-*Lrrk2tm1.*\     Jackson Laboratory                       JAX stock \#009346   [@bib38]
  background\                  *1Shn*/J mouse,                                                                      
  (*Mus musculus)*                                                                                                  

  Strain, strain\              SA Sprague\            Charles River                            Crl:SD/code 400      [@bib11]\
  background\                  Dawley rat                                                                           
  (*Rattus norvegicus*)                                                                                             

  Genetic reagent\             human Rab10            TRCN0000029191                                                
  (shRNA) / (*Homo sapiens*)                                                                                        

  Genetic reagent\             human Rab8a            TRCN0000300539                                                
  (shRNA) / (*Homo sapiens*)                                                                                        

  Genetic reagent\             human RILPL1           TRCN0000159762                                                
  (shRNA) / (*Homo sapiens*)                                                                                        

  Genetic reagent\             mouse RILPL1           TRCN0000033243                                                
  (shRNA) / (*Mus musculus*)                                                                                        

  Genetic reagent\             mouse Rab8a            TRCN0000100422                                                
  (shRNA) / (*Mus musculus*)                                                                                        

  Cell line\                   A549 Rab8 KO           PMID: 29125462                                                
  (*Homo sapiens*)                                                                                                  

  Cell line\                   A549 Rab10 KO          PMID: 29125462                                                
  (*Homo sapiens*)                                                                                                  

  Cell line\                   A549                   PMID: 29125462                                                
  (*Homo sapiens*)                                                                                                  

  Cell line\                   HEK293T                <https://mrcppureagents.dundee.ac.uk/>                        
  (*Homo sapiens*)                                                                                                  

  Cell line\                   MEF-R1441G             <https://mrcppureagents.dundee.ac.uk/>                        
  (*Mus musculus*)                                                                                                  

  Cell line\                   hTert-RPE              ATCC                                                          
  (*Homo sapiens*)                                                                                                  

  Cell line\                   HeLa                   ATCC                                                          
  (*Homo sapiens*)                                                                                                  

  Cell line\                   human iPSC             PMID: 24148854                                                [@bib31]\
  (*Homo sapiens*)                                                                                                  

  Recombinant\                 pMCB306-\              PMID: 29125462                                                [@bib36]\
  DNA reagent                  eGFP-Rab8                                                                            [@bib36]

  Recombinant\                 pMCB306-\              PMID: 9212815                                                 [@bib28]
  DNA reagent                  eGFP-Rab10                                                                           

  Recombinant\                 pMCB306-\              PMID: 9212815                                                 [@bib28]
  DNA reagent                  eGFP-LRRK2                                                                           

  Recombinant\                 pENTR-2x-\             Addgene                                  25361                
  DNA reagent\                 myc-LRRK2                                                                            

  Recombinant\                 pcDNA5D-\              PMID: 29125462                                                [@bib36]\
  DNA reagent                  FRT-TO-RILPL1                                                                        [@bib36]

  Transfected\                 RILPL1                 <https://mrcppureagents.dundee.ac.uk/>   DU57861              
  construct (gRNA)                                                                                                  

  Transfected\                 RILPL1                 <https://mrcppureagents.dundee.ac.uk/>   DU57867              
  construct (gRNA)                                                                                                  

  Antibody                     rabbit\                Sigma                                    HPA-014314           (1:500)
                               monoclonal\                                                                          
                               anti-RILPL1                                                                          

  Antibody                     rabbit\                Cell Signaling                           8127                 (1:1000)
                               monoclonal\                                                                          
                               anti-Rab10                                                                           

  Antibody                     rabbit\                Abcam                                    AB133518             (1:1000)
                               monoclonal\                                                                          
                               anti-LRRK2                                                                           

  Antibody                     rabbit\                Abcam                                    AB230261             (1:2000)
                               monoclonal\                                                                          
                               anti-phospho T73\                                                                    
                               Rab10                                                                                

  Antibody                     rabbit\                Cell Signaling                           6975                 (1:200)
                               monoclonal\                                                                          
                               anti-Rab8                                                                            

  Antibody                     mouse\                 9E10 clone\                                                   (1:1)
                               monoclonal\            hybridoma                                                     
                               anti-myc                                                                             

  Antibody                     chicken\               Novus Biologicals                        NBP1-05198           (1:5000)
                               polyclonal\                                                                          
                               anti-GFAP                                                                            

  Antibody                     goat polyclonal\       Millipore                                AB144P               (1:200)
                               anti-choline acetyl\                                                                 
                               transferase                                                                          

  Antibody                     mouse\                 Neuromab                                 75--287              (1:2000)
                               monoclonal\                                                                          
                               anti-Arl13b\                                                                         

  Antibody                     mouse\                 Santa Cruz                               SC-515403            (1:200)
                               monoclonal\                                                                          
                               anti-Cep164                                                                          

  Antibody                     rabbit\                Santa Cruz                               SC-588               (1:100)
                               polyclonal\                                                                          
                               anti-adenylate\                                                                      
                               cyclase 3                                                                            

  Antibody                     mouse\                 Biolegend                                834501               (1:2000)
                               monoclonal\                                                                          
                               anti-NeuN                                                                            

  Antibody                     mouse\                 Neuromab                                 N86-38               (1:2000)
                               monoclonal\                                                                          
                               anti-GFP                                                                             

  Chemical\                    Lipofectamine\         Life Technologies                                             
  compound,\                   3000                                                                                 
  drug                                                                                                              

  Chemical\                    MLi2                   PMID: 29125462                                                
  compound,\                                                                                                        
  drug                                                                                                              

  Software,\                   FIJI                                                                                 
  algorithm                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------

Reagents {#s4-1}
--------

MLi2 LRRK2 inhibitor ([@bib34]) was synthesized as described in ([@bib24]). All DNA constructs and antibodies generated for the experiments are described in ([@bib28]) and can be found at <https://mrcppureagents.dundee.ac.uk.>

General cloning and plasmids {#s4-2}
----------------------------

DNA constructs were amplified in *E. coli* DH5α and purified using mini prep columns (Econospin). DNA sequence verification of all plasmids was performed by Sequetech (<http://www.sequetech.com>). The following constructs were used: eGFP-Rab8A and eGFP-Rab10 were cloned into lentivirus vector pSLQ1371 between BstB1 and AvrII sites ([@bib28]). Rab8A T72E/A and Rab10 T73E/A were generated by site directed mutagenesis using Pfu polymerase (Agilent Technologies). eGFP-LRRK2-G2019S was cloned into modified pSLQ1371 with eGFP at the N-terminus. Myc-LRRK2 was obtained from Addgene (\#25361) and the R1441G mutation was introduced as described ([@bib28]). RILPL1 was cloned into pcDNA5d/FRT/TO using Gibson assembly and RILPL1-C and RILPL1-N were made by site directed mutagenesis. Lentiviral shRNA pLKO.1 plasmids were obtained as bacterial stocks from Sigma: mouse Rab8A (TRCN0000100422), human Rab8A (RCN0000300539), human Rab10 (TRCN0000029191), mouse Rab10 (TRCN0000335543), mouse RILPL1 (TRCN0000033243) and human RILPL1 (UTR TRCN0000159762). For human Rab10, pSIH vector was also used with a GFP reporter. The shRNA sequence for hRab10 5\'- GATCCGAAGATCAAGCTACAGATCTTCCTGTCAGAATCTGTAGCTTGATCTTCTTTTTG was cloned using *EcoRI* and *BamHI* restriction sites.

Cell culture, transfections and ciliogenesis {#s4-3}
--------------------------------------------

HEK293T, HeLa, A549 and hTERT-RPE cells were obtained from ATCC and were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM Glutamine, penicillin (100 U/ml)/streptomycin (100 µg/ml) and non-essential amino acids. HEK293T cells were transfected with Polyethylenimine HCl MAX 4000 (PEI) (Polysciences, Inc.) as described (Reed et al., 2006). RPE and HeLa cells were transfected with Fugene6 (Promega) while rat astrocytes and A549 cells were transfected using lipofectamine 3000 according to the manufacturer. Cells were checked routinely for Mycoplasma using either MycoALert Mycoplasma Detection Kit (Lonza LT07-318) or PCR.

Human iPS and rat astrocyte cell culture {#s4-4}
----------------------------------------

Human patient derived G2019S = NM_198578.3 (*LRRK2)*: c.6055G \> A (p.Gly2019Ser) iPS cultures were maintained as described ([@bib31]). Cells were plated on 4% matrigel coated, 24 well plates. Colonies of iPS cells were dissociated with Accutase, and resuspended in mTesR medium with 10 µM Y-27632. Cultures of primary rat astrocytes were obtained by antibody panning from rat pups as described ([@bib11]). In brief, six to ten postnatal Sprague-Dawley rat cortices were mechanically and enzymatically dissociated to produce single cells. They were passed over successive, antibody-coated negative panning plates to rid the suspension of microglia, endothelial cells, and oligodendrocyte precursor cells before selecting for astrocytes with an anti-ITGB5-coated plate. Astrocytes that attached to the anti-ITGB5-coated plate were trypsinized and plated onto poly-D lysine coated ACLAR coverslips. Cells were incubated at 37°C with 10% CO~2~ and 90% O~2~ for one to three weeks.

Lentivirus production {#s4-5}
---------------------

Lentivirus-based shRNA was used for gene knockdown of human Rab8A, mouse/human Rab10, mouse/human RILPL1 using pLKO or pSIH-GFP vector. The lentiviral vector was co-transfected with packaging vectors psPAX2, pMD2 VSV-G in HEK293T cells using PEI. pLKO-puro-scramble or pSIH-GFP-scramble was used as control. After 48 hr, culture supernatants were collected and virus concentrated 10x overnight with Lenti-X concentrator (Clontech) according to the manufacturer. Virus was transduced onto target cells with polybrene (2 µg/ml). To make stable cells, infected cells were selected with puromycin (0.2--1 µg/ml) 48 hr after infection. Expression of the target protein was verified by GFP-fluorescence, qPCR and/or immunoblotting.

Lysis and immunoblotting {#s4-6}
------------------------

Cells were lysed 24 hr after transfection in ice-cold lysis buffer containing 50 mM Tris/HCl, pH 7.5, 1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF, 10 mM 2-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 μg/ml mycrocystin-LR (Enzo Life Sciences), and EDTA-free protease inhibitor cocktail (Sigma). Lysates were centrifuged at 13800 x *g* for 15 min at 4°C and supernatants were quantified by Bradford assay (Thermo Scientific) and 60 µg of proteins used for immunoblotting. Antibodies were diluted in blocking buffer containing 5% milk in 0.05% Tween in Tris buffered saline (TBS) and incubated overnight on the blots.

Inducing primary cilia {#s4-7}
----------------------

Cells were grown to confluency in DMEM with serum. Mouse embryonic fibroblasts (MEFs) (WT and R1441G) as well as hTERT-RPE cells were ciliated by overnight serum starvation in DMEM medium alone. For A549 cells, cells were plated at 80% confluency and 24 hr later, subjected to 2% serum for 48 hr. Neither rat astrocytes nor iPS cells needed cilia induction. Rat astrocytes made primary cilia after one week in culture while undifferentiated iPS cells made cilia by 72 hr in culture on matrigel. To identify primary cilia, cells were stained for cilia markers Arl13b or acetylated tubulin.

Membrane fractionation {#s4-8}
----------------------

Cells were chilled on ice, washed with ice cold PBS, and swelled in 10 mM HEPES pH 7.4. After 15 min, 5X buffer was added to achieve a final concentration of resuspension buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM MgCl~2~, 2 mM DTT, 20 µM GDP, 1X protease inhibitor cocktail (Sigma)), and the suspension was passed 20 times through a 25 gauge syringe. Nuclei were pelleted by centrifugation at 1,000 X *g* for 5 min at 4°C. The postnuclear supernatant was spun 100,000 X *g* for 20 min in a table top ultracentrifuge in TLA100.2 rotor; the resulting supernatant was the cytosol fraction. Membrane pellets were solubilized in 1% Triton X100 containing 1X resuspension buffer. Protein was estimated by Bradford assay (BioRad, Richmond, CA). Samples containing 25 μg of membrane protein, or the equivalent volume of cytosolic protein, were heated at 95°C for 2 min after addition of 5X SDS--PAGE sample buffer. Samples were loaded in duplicate onto 12% SDS-PAGE gels for imunoblotting; filters were incubated with chicken anti-GFP (Aves, 1:2000) overnight then with donkey anti‐chicken 680 (Licor, 1:10,000) for 1 hr, imaged using an Odyssey Infrared scanner (Licor), and quantified using ImageJ software.

Hedgehog signaling {#s4-9}
------------------

MEFs were cultured in 24 well plates, and upon confluency, serum starved in DMEM and treated with 200 nM MLi2 or DMSO. At the same time, cells were treated with either 25 nM Sonic hedgehog (Shh) or PBS. After 16 hr ± MLi2,±Shh treatment, cells were lysed for RNA extraction and qPCR of Gli1 mRNA. Human patient derived iPS cells already have high Gli1 levels and did not need Shh treatment; iPS cells were lysed for qPCR analysis of Gli1 after 72 hr.

Quantitative PCR {#s4-10}
----------------

To extract total RNA, cells are lysed in Trizol (Sigma) for 5 min in an RNA-free zone. RNA extraction was performed using chloroform/isopropyl alcohol according to the manufacturer. RNA was stored at −80°C. cDNA was synthesized using 500 ng to 1 µg RNA using high capacity cDNA synthesis kit with multiscribe reverse transcriptase (Applied Biosystems). The cDNA was diluted 50 fold and 1 µl cDNA was used as template in the PowerUp SYBR green 2X master mix and analyzed in a qPCR machine (7900HT Applied Biosystems). Gene expression was compared using 2\^(delta-delta Ct) method with GAPDH or Actin as internal controls. The primers used for the qPCR were as follows -- RAB10 HGNC:9759 -fw-GTGGGGAAGACCTGCGTCCTTT, rv- GAGGTTGTGATGGTGTGAAATCGC; RAB8A HGNC:7007 -fw**--**CTGGCGAGAGTGAAAAATGC, rv--AAAAGCTGGCCCTCGACTAT; RILPL1 HGNC:26814-fw--ATGGAAGAGGAAAACCGAATACC, rv--AGGCGCTTCTTATCTCGGGA; ACT HGNC:929-fw--GGCATCCTCACCCTGAAGTA,rv--AGAGGCGTACAGGGATAGCA; HPRT1 HGNC:5157-fw--GGTCAGGCAGTATAATCCAAAG, rv--GGACTCCAGATGTTTCCAAAC; GLI1 HGNC:4317 -fw--GAAGTCATACTCACGCCTCGAA, rv--CAGCCAGGGAGCTTACATACAT; Mus musculus GAPDH-fw--AGGTCGGTGTGAACGGATTTG, rv--TGTAGACCATGTAGTTGAGGTCA; Mus musculus RAB10-fw--GGCAAGACCTGCGTCCTTTT, rv--GTGATGGTGTGAAATCGCTCC; mRILPL1-fw--GGTTGCGCGTAGAGAGGATG, rv--CTCACGCTCTGACATGCCTTC; Mus musculus GLI1-fw- CCAAGCCAACTTTATGTCAGGG, rv- AGCCCGCTTCTTTGTTAATTTGA.

Generation of mutant mice {#s4-11}
-------------------------

The LRRK2^R1441C/R1441C^ mice were obtained from The Jackson Laboratory (B6.Cg-*Lrrk2^tm1.1Shn^*/J mouse, JAX stock \#009346; [@bib38]) and kept in specific pathogen-free conditions at the University of Dundee (UK). All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and regulations set by the University of Dundee and the U.K. Home Office. Animal studies and breeding were approved by the University of Dundee ethical committee and performed under a U.K. Home Office project license. Mice were multiply housed at an ambient temperature (20--24°C) and humidity (45--55%) and maintained on a 12 hr light/12 hr dark cycle, with free access to food (SDS RM No. three autoclavable) and water. Genotyping of mice was performed by PCR using genomic DNA isolated from ear biopsies. Primer 1 (5' -CTGCAGGCTACTAGATGGTCAAGGT −3') and Primer 2 (5' --CTAGATAGGACCGAGTGTCGCAGAG- 3') were used to detect the wild-type and knock-in alleles. Homozygous LRRK2-R1441C and littermate wild-type controls (7 months of age) were used for experiments shown in [Figure 8](#fig8){ref-type="fig"}. The genotype of these mice was confirmed by PCR on the day of experiment.

Generation of knock out A549 cells {#s4-12}
----------------------------------

A549 Rab8A knockout ([@bib36]) and Rab10 knock-out ([@bib15]) cell lines have been described ([@bib36]). The A549 RILPL1 knockout cell line was generated using sense and anti-sense paired guides DU57861 and DU57867 (available at <https://mrcppureagents.dundee.ac.uk>), targeting exon 3 of RILPL1; sense guide: GGTGATGAAGAAGCTGAAGG (DU57861); anti-sense guide: GCTCCCGCTCTGACATGCCT (DU57867). Cells at about 80% confluency were co-transfected in a six-well plate with the pair of constructs using Lipofectamine LTX reagent (9 μl Lipofectamine LTX and 2.5 mg DNA per well). After 24 hr transfection, the medium was replaced with medium Supplemented with puromycin (2 mg/ml). After 24 hr selection, the medium was replaced with medium without puromycin and cells were left to recover for 48 hr before performing single-cell sorting using an Influx cell sorter (Becton Dickinson). Single cells were placed in individual wells of a 96-well plate containing DMEM Supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin,100 mg/ml streptomycin and 100 mg/ml normocin (InvivoGen). At about 80% confluency individual clones were transferred into six-well plates and screened for RILPL1 knock-out by immunoblotting.

Light microscopy  {#s4-13}
-----------------

Cells were plated on collagen coated coverslips transfected with indicated plasmids. Cells were fixed with 3% paraformaldehyde for 20 min, permeabilized for 3 min in 0.1% Triton X 100 (or 0.1% saponin for anti-phospho Rab10 antibody staining) and blocked with 1% BSA in PBS. Antibodies were diluted as follows: mouse anti-Arl13b (1:1000, Neuromab), mouse anti-GFP (Neuromab, 1:1000); mouse anti-Myc (9E10 Hybridoma culture supernatant -- 1:2), rabbit anti-RILPL1 (Sigma, 1:500), rabbit anti-GCC185 (Cheung et al. 2015, 1:1000), rabbit anti phospho Rab10 (1:1000, Abcam), rabbit anti adenylate cyclase III (Santa Cruz 1:100), mouse anti-NeuN (Proteintech, 1:1000), goat anti choline acetyltransferase (Millipore 1:100), rabbit anti Rab8A and Rab10 (1:1000, Cell Signaling), rabbit anti RILPL1 antibody ([@bib36]), mouse anti tubulin (1:2000, Sigma), mouse anti acetylated tubulin (1:2000, Sigma), mouse anti Centrin-3 (gift from Tim Stearns, Stanford), chicken anti GFAP (1:5000, Novus Biologicals), mouse anti Transferrin receptor (1:500, BD Bioscience). Highly cross absorbed H + L secondary antibodies (Life Technologies) conjugated to Alexa 488, Alexa 568 or Alexa 647 were used at 1:2000 or 1:4000. All antibody dilutions for tissue staining included 1% DMSO to help antibody penetration. All images were obtained using a spinning disk confocal microscope (Yokogawa) with an electron multiplying charge coupled device (EMCCD) camera (Andor, UK) and a 100 × 1.4 NA oil immersion objective. Images were analyzed using Fiji (<https://fiji.sc/>) and whenever necessary, were presented as maximum intensity projections. Nuclei were stained using 0.1 µg/ml DAPI (Sigma).

In vitro prenylation {#s4-14}
--------------------

For in vitro prenylation, cytosol obtained from membrane fractionation was incubated with 6.7 µM biotin-geranyl pyrophosphate (Jena Bioscience) for 4 hr, rotating at room temperature. GFP-Rab8A or GFP-Rab10 were then immunoprecipitated using GFP binding protein immobilized on Sepharose for 1 hr at 4°C. Resin was washed 3 times with 1X membrane fractionation resuspension buffer and eluted with 2X SDS-PAGE sample buffer. The elutions were run on 12% SDS-PAGE gels for immunoblotting, detecting prenylation Streptavidin 800 nm (Licor, 1:1000) then chicken anti GFP (Aves 1:2000). Membranes were incubated with donkey anti chicken 680 (Licor 1:10,000) for 1 hr, imaged using an Odyssey Infrared scanner (Licor0 and quantified using ImageJ software. For Rab8A, dishes were treated with 10 µM lovastatin 16 hr before lysis---because Rab8A is monoprenylated, this increased the pool of non-prenylated Rab8A in the cytosol, enabling us to assay for prenylation capacity in vitro.

Mouse brain processing and primary cilia analyses {#s4-15}
-------------------------------------------------

Homozygous LRRK2-R1441C and littermate wild-type controls (7 months of age) were terminally anesthetized and perfused by injection of PBS into the left cardiac ventricle followed by injection of 4% paraformaldehyde in PBS before collecting the brains for analysis. Mice brains were immersed in 30% sucrose for 2 days until they were completely submerged. Brains were then embedded in plastic blocks with OCT (BioTek, USA), frozen on dry ice and stored at −80°C. While embedding, the anterior and posterior sides of the brains in the block were noted. For cryosectioning, OCT blocks were kept at −20°C for 10 min. The brains were oriented to cut sagittal sections on the cryotome (Leica CM3050S, Germany) at 16 µm thickness and adhered onto SuperFrost plus tissue slides (Thermo Fisher, USA). This orientation helped in visualizing cortex, hippocampus and striatal regions ([Figure 8G](#fig8){ref-type="fig"}).

Slices closest to the midline were chosen for immunostaining. For primary cilia staining in brain sections, frozen slides were thawed at RT for 10 min then gently washed with PBS for 5 min. Sections were permeabilized with 0.1% Triton X-100 in PBS at room temperature for 15 min. Sections were blocked with 1% bovine serum albumin and 2% bovine calf serum in PBS for 2 hr at RT. Sections were incubated overnight with primary rabbit polyclonal antibodies and incubated with secondary antibodies (Thermo Scientific, 1:1000) at room temperature for 2 hr. Stained tissues were overlayed with Mowiol and a glass coverslip. Three brain areas were chosen -- Somatosensory area of the cerebral cortex, pyramidal layer of the hippocampus and striatal area of the caudoputamen, adjacent to the lateral ventricle. Four to five regions within each brain area were imaged using 0.75 µm Z-sampling for each mouse brain. All image visualizations and analyses were performed using Fiji (<https://fiji.sc>). To analyze primary cilia, maximum intensity projections of Z-stacks were median filtered, thresholded and the resulting mask was subjected to the skeletonize function. Number of Primary cilia structures in these masks were then counted using Analyze \> Analyze Particles. To measure primary cilia lengths, the output image from the previous step was subsequently analyzed using Analyze \> Skeleton \> Analyze Skeleton \> Longest shortest path function. The number of nuclei in the cerebral cortex and striatal regions of the brain were determined by analyzing maximum intensity projections of the DAPI channel. The image was median filtered, subjected to 'Fill Holes', 'Watershed' followed by Analyze \> Analyze Particles. The number of nuclei in the pyramidal layer of the hippocampus was determined manually by differential pseudo-coloring of the Z-stack to overcome counting errors caused by tight packing of the nuclei and intense nucleoli staining of neurons in this region. For cilia analysis of iPS cells, undifferentiated cells were plated on matrigel coated coverslips and cultured for 72 hr; the cells were subconfluent, two dimensional monolayers rather than organoids. Upon confluency (5 days), they lose their ciliation and were not analyzed further.

### Quantitation of centriolar distance {#s4-15-1}

A549 cells transfected with RILPL1-GFP and stained for Centrin-3 or gamma tubulin were imaged on a confocal microscope with Z-step size of 0.5 µm. Distances were quantified from cells where only two dots were visible; cells in mitosis were excluded based on nuclear DAPI staining. Only a single plane from a Z-stack was used to quantify the distance between centrioles to eliminate error introduced by Z-sampling. The distance was measured using FIJI (<https://fiji.sc>) by drawing a straight line between the centers of the centriole dots. RILPL1 expression was quantified in FIJI by first subtracting background from the sum-intensity projection images, outlining the cells, followed by measuring the integrated density of the signal from a single cell.

### Statistics {#s4-15-2}

Graphs were made using Graphpad Prism six software. Error bars indicate SEM. Unless specified, a Student's T-test was used to test significance. Two tailed p-values\<0.05 were considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter, peer reviews, and accompanying author responses.

\[**Editorial note:** This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor\'s assessment is that all the issues have been addressed.\]

Thank you for submitting your article \"A pathway for Parkinson\'s Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Christopher G Burd as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Vivek Malhotra as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Peter Novick (Reviewer \#3). Reviewer \#2 remains anonymous.

The Reviewing Editor has highlighted the concerns that require revision and/or responses, and we have included the separate reviews below for your consideration. If you have any questions, please do not hesitate to contact us.

Summary:

The manuscript presents an investigation into the roles of LRRK2, Rab8A, Rab10, and RILPL1 in ciliogenesis and report that Parkinson\'s Disease-associated alterations in LRRK2 activity lead to compromised cilium assembly and Hedgehog signaling. Overall, the reviewers considered the conclusion that LRRK2 regulates the activities of Rab8 and Rab10 in ciliogenesis to be well supported by the data. Although the study provides little mechanistic insight into the specific functions of Rab8 and Rab10 in ciliogenesis, it does provide an interesting and potentially important insight into the etiology of Parkinson\'s disease.

Major concerns:

1\) It is not firmly established that Rab8 and Rab10 play important roles in ciliogenesis in cell types other than the A549 cell line (see reviewer 2, major comment 1), which is not commonly used for investigating ciliogenesis. The impact of the work could be better evaluated by repeating a limited number of key experiments in RPE cells or wildtype MEFs (e.g. to show that Rab10/RILPL1 can inhibit ciliogenesis in these cells). This seems to have been addressed with experiments done using RPE cells (subsection "Rab8 activates while Rab10 inhibits cilia formation in A549 cells", first paragraph), but the data is not shown. At a minimum, this data should be shown.

2\) Neither the Rab8 or Rab10 T-to-E/A mutant proteins are functional and it seems likely that the mutant Rabs are non-functional independent of their presumed effects on phosphorylation, and this point is not adequately explored or clearly conveyed. It is shown that Rab10 T73A is cytosolic, explaining why it is non-functional. Why are the other rab8 and Rab10 mutants non-functional? Are they isoprenylated? If the mutants do not selectively affect phosphorylation (e.g. they alter isoprenylation), their use seems tangential to the main point of the paper.

3\) The effect of the Rab10 LRRK2 phosphorylation site mutations (T73A, E) on its association with RILP1 should be determined, similar to the analysis of Rab8 mutants and RILP1 (Figure 3---figure supplement 1). This information is important for interpreting the phenotypes of the mutant proteins.

4\) Please note that each of the reviewers were confused by certain aspects of the presentation (see the reviews). I encourage you to consider revising the presentation to address these sources of confusion.

Separate reviews (please respond to each point):

*Reviewer \#1:*

This study addresses the role of LRRK, a protein kinase implicated in Parkinson\'s disease, in ciliogenesis. Mutations in LRRK that cause PD activate its protein kinase activity, but how this leads to PD is unknown. The study follows an earlier publication that reported that Rab proteins are the principal substrates for LRRK, including Rab8 and Rab10, the focus of this study. Rab8 has previously been implicated in ciliogenesis, and the authors present evidence that phosphorylation of Rab8 by LRRK inhibits its function in ciliogenesis. In contrast, the authors find that depletion of Rab10, another Rab GTPase implicated in ciliogenesis, potentiates ciliogenesis and that phosphorylation of Rab10 by LRRK potentiates its inhibitory effect on ciliogenesis via enhanced interaction with RILPL1, a Rab10 effector of unknown function. It is shown that depletion of RILPL1 potentiates ciliogenesis, similar to depletion of Rab10. Finally, it is shown that PD mutations in LRRK cause a decrease in the proportion of ciliated cells and deficient SSH signaling in striatal cholinergic neurons of the mouse brain. The specific functions of Rab8 or Rab10 in ciliogenesis or PD are largely unknown. This is a technically sound, well controlled study, that clearly supports roles for Rab8 and Rab10 in ciliogenesis, though if these GTPases play direct, specific roles in ciliogenesis remains an open question. In my opinion, the major value of this study lies in the identification of functional consequences for LRRK-mediated phosphorylation of Rab8 and Rab10 in ciliogenesis, a finding that puts a spotlight on ciliogenesis for future studies of PD etiology.

Phenotypic analyses of Rab8a/b knockout mice by Sato et al., 2014, showed essentially no effect on cilia number and little evidence of ciliopathies that would be expected by the loss of a key factor in ciliogenesis. Moreover, they reported that knockout of Rab10 resulted in a loss of cilia, the opposite reported here. How do the authors reconcile these published observations with their results? If I understand correctly, the authors propose that Rab8 \"activates\" ciliogenesis, rather than provides an essential role, but it is unclear to me what \"activate\" means.

It is shown that loss of RILPL1 potentiates ciliogenesis, similar to loss of Rab10. It is also shown that Rab10 does not require RILPL1 for its effects on ciliogenesis (\"This suggests that Rab8A and Rab10 do not require RILPL1 for their effects on ciliogenesis...\"). So why are Rab10 and RILPL1 proposed (\"LRRK2 kinase acts via a pRab10-RILPL1 pathway to inhibit ciliogenesis\") to function on the same ciliogenesis pathway? It would be helpful if the authors clarified this conclusion.

Additional data files and statistical comments:

Rigour and extent of the statistical information are satisfactory.

*Reviewer \#2:*

Here, Dhekne et al. investigate the roles of LRRK2, Rab8A, Rab10, and RILPL1 in ciliogenesis and report that Parkinson\'s Disease-associated alterations in LRRK2 activity lead to compromised cilium assembly and Hedgehog signaling, which may contribute to Parkinson\'s pathogenesis. This study builds on two recent reports in *eLife* from these groups (working also with Matthias Mann\'s group) that identified Rab8A and Rab10 as LRRK2 substrates, characterized phosphorylation-dependent binding of RILPL1 to these Rab\'s, and found reduced ciliogenesis in fibroblasts with elevated LRRK2 activity. In this manuscript, the authors investigate how Rab8A, Rab10, and RILPL1 control ciliogenesis downstream of LRRK2, finding that Rab8A promotes ciliogenesis (as previously reported), while RILPL1 promotes Rab10-dependent inhibition of cilium formation. Additionally, the authors show that increased LRRK2 activity leads to decreased reduced ciliogenesis (in MEFs, human iPS cells and mouse brain) and diminished cilium-dependent Hedgehog signaling (in MEFs and human iPS cells).

The negative regulation of ciliogenesis by Rab10/RILPL1 is an interesting finding that, if generalizable to other cell types/tissues, represents a novel insight into ciliogenesis that motivates future analysis of the underlying mechanism. Additionally, the findings that LRRK2 hyper-activity inhibits ciliogenesis and blunts Hedgehog signaling provide further evidence that ciliary defects may contribute to Parkinson\'s Disease. Lastly, the observation that Rab10 knockdown suppresses ciliogenesis defects seen in MEFs with elevated LRRK2 activity provides an important connection between the two aforementioned findings. As detailed below, the study could be strengthened by further examining Rab10\'s role in ciliogenesis in cell lines that are more commonly used to study cilia. Additionally, some data are presented in a confusing manner and do not support some of the conclusions reached. These unclear sections significantly obscure the key results and should be revised before publication in *eLife*.

1\) Many of the experiments are done in A549 cells, but A549 cells ciliate at a relatively low rate (\~25%) and are not commonly used to study ciliogenesis. Thus, it is possible that the inhibitory effects on ciliogenesis of Rab10/RILPL1 may be a distinct feature of this cell type rather than indicative of a more general role for these proteins in regulating cilium formation (especially as Sato et al., 2014, reported Rab10 to be instead a positive regulator of ciliogenesis that acts redundantly with Rab8A and Rab8B). This concern is partially mitigated by the data from LRRK2-R1441G MEFs shown in Figure 6, but it would nonetheless be helpful to repeat a limited number of key experiments in RPE cells or wildtype MEFs (e.g. to show that Rab10/RILPL1 can inhibit ciliogenesis in these cells). In the first paragraph of the subsection "Rab8 activates while Rab10 inhibits cilia formation in A549 cells", the authors note that cilia were examined in RPE cells following knockdown of Rab8A and Rab10, but the data are not shown.

2\) Several sections of the Results are confusing and should be revised (see Minor Comments 1-5 for details).

3\) While the authors have tested the functional interdependencies among LRRK2, Rab8A, Rab10, and RILPL1, the bigger picture of how these proteins interact to control ciliogenesis remains unclear with respect to where Rab8A fits in. Could the authors integrate Rab8A into a pathway model like that in Figure 6D? It seems that one possible model is RILPL1 \--\| Rab8A \--\| Rab10 \--\| ciliogenesis, with LRRK2 promoting Rab10 activity, but this diverges a bit from Figure 6D and perhaps there are alternatives that fit better or otherwise merit consideration. Lastly, given the evidence that Rab10 can inhibit ciliogenesis in the absence of RILPL1, are there Rab10 effectors that the authors view as good candidates for mediating Rab10\'s inhibition of ciliogenesis?

Minor Comments:

1\) The authors state, \"addition of exogenous Rab10 suppresses cilia formation in cells lacking Rab8A or Rab10. Moreover, Rab8A enhances cilia formation in cells lacking Rab10; thus this represents an independent pathway for ciliogenesis activation\". First, the effect of exogenous Rab10 expression on ciliogenesis in Rab8A-deficient cells does not appear to have been examined here. Second, the data indicate that Rab8A does not enhance cilium formation in cells lacking Rab10; rather, Figure 2B shows that cells lacking Rab10 bypass Rab8A\'s normal role in promoting ciliogenesis -- itself a striking finding. Finally, this section concludes by discussing evidence from Sato et al. that Rab8A/B double-mutant mice show normal primary cilia. This fact seems to confuse or contradict the present data; it may be helpful instead to discuss the findings of Sato et al., 2014, in the Discussion.

2\) The conclusions that can be drawn from the use of phospho-site T-\>A and T-\>E mutants are also not clear. As the authors note, the Rab10A T73A appears to be non-functional and should not be used as a phosphorylation-blocking allele. Given that Rab8A T72A and T72E mutants both fail to rescue ciliogenesis defects in Rab8A knockout cells and interact poorly with RILPL1 (while phosphorylated Rab8A robustly binds RILPL1), it is likely these mutants are non-functional and do not specifically block or mimic phosphorylation. Thus, the statement in the Abstract that \"Rab8A phosphorylation blocks its ability to promote ciliogenesis\" should be revised. Also, is the more potent inhibition of ciliogenesis by the Rab10 T73E mutant relative to wildtype Rab10 statistically significant?

3\) The order of data presented in the text does not closely follow the order of data in the figures, especially for the first 2 figures and Figure 3---figure supplement 1. Adjusting the order of the figure panels would make the paper easier to follow. Also, in the first paragraph of the subsection "RILPL1 regulates pRab10 localization", the reference to Figure 3---figure -- supplement 1 appears to instead refer to Figure 5---figure -- supplement 1. In the first paragraph of the subsection "RILPL1 regulates pRab10 localization", the reference to Figure 4B appears to refer instead to Figure 4A. Lastly, what is being shown in Figure 2A with respect to GFP-Rab8 and GFP-Rab10?

4\) An additional area of confusion is in the section titled, \"RILPL1 suppresses cilia formation via centrioles\". It seems from the data in Figure 5F-H that, contrary to the section title, RILPL1 suppresses cilia formation independently of effects on centriole spacing. Additionally, while the effects on ciliogenesis of RILPL1 expression in RILPL1 KO cells are striking, it would be informative to assess whether a similar inhibition of ciliogenesis occurs when RILPL1 is over-expressed in wildtype cells.

5\) In Figure 4, the authors analyze the effects of RILPL1 fragments on pRab10 localization. While the reported effects are interesting, the suggestion \"that the RILPL1 N-terminus interacts with pRab10 in pericentriolar membranes\" should perhaps be tempered given that a prior report from these groups showed that it is the C-terminal RH domain in RILPL1 that mediates interaction with Rab8A (PMID: 29125462), and the same may be true for Rab10 (even considering the data shown).

6\) The results from LRRK2-G2019S iPS cells in Figure 7C-E could be attributed to differences in ciliogenesis associated with the process of deriving the mutant versus wildtype lines. This potential concern could be alleviated by examining whether MLi2 treatment restores normal levels of cilium formation to the G2019S cells.

7\) The authors state that \"Yoshimura et al., 2007, were the first to show that Rab8A, but not Rab8B, is the only Rab GTPase to localize to primary cilia in hTert-RPE1 cells\". This statement may be misleading to some readers given subsequent evidence that GFP-Rab23 localizes to RPE1 cilia (PMID: 26136363), as does Rab8B (PMID: 21273506). Additionally, while Rab8 and Rabin8 promote ciliogenesis, this effect appears to be only partly through the BBSome and may instead be primarily related to delivery of membrane vesicles to the growing cilium (e.g. PMID: 25812525).

*Reviewer \#3:*

This paper evaluates the role of the Rab8 and Rab10 GTPases as well as the Rab effector RILPL1 in the regulation of ciliogenesis by the LRRK2 kinase. It then goes on to explore the role of changes in ciliogenesis in mediating the effects of LRRK2 in Parkinson's disease. In general the studies are well designed and well executed and the results are by in large convincing. While the paper probably opens as many questions as it closes, it represents an important advance in understanding one molecular mechanism underlying a genetic cause of Parkinsons and should have a broad audience. Below I have outlined a number of points that should be explored more thoroughly or, in one case, deleted for clarity.

1\) In Figure 1D and E what is the level of expression of Rab8 and 10 and their mutant alleles relative to the endogenous level? It looks very high.

2\) The relationship of Rab8 to Rab10 has not been explored in depth. Does the loss or overexpression of one affect the localization of the other at the cilia? Does the loss or overexpression of one affect the activation of the other? They are closely related and can both bind RILPL, how does each affect the interaction of the other with this common effector? They interpret their data to indicate that the effects of each on ciliogenesis are totally independent of the other, but I am not so sure.

3\) In Figure 2B, C and D a WT control is needed.

4\) The text refers to cells in which a component is knocked out by CRISPR as \"depleted\". It would be more accurate to say that the component is deleted. Depletion suggests a partial loss.

5\) In Figure 2E they should also test the membrane association of the Rab8 mutants. Directly testing for isoprenylation of the various Rab8 and 10 alleles would address the issue more clearly.

6\) Figure 3---figure supplement 1 looks at the effect of phosphorylation on the interaction of Rab8 with RILPL, however the effects on ciliogenesis are predominantly mediated by Rab10. They should also explore the effects of phosphorylation of Rab10 on its interaction with RILPL.

7\) The discussion of the effects of RILPL on centriolar distance is very confusing and appears to be of no obvious relevance to this story. In Figure 5G and H it looks like there is an effect, but in 5I it looks like there isn\'t a significant effect. This is confusing. I would suggest deletion of this section of the paper as it distracts from the main line of reasoning.

10.7554/eLife.40202.019

Author response

> Major concerns:
>
> 1\) It is not firmly established that Rab8 and Rab10 play important roles in ciliogenesis in cell types other than the A549 cell line (see reviewer 2, major comment 1), which is not commonly used for investigating ciliogenesis. The impact of the work could be better evaluated by repeating a limited number of key experiments in RPE cells or wildtype MEFs (e.g. to show that Rab10/RILPL1 can inhibit ciliogenesis in these cells). This seems to have been addressed with experiments done using RPE cells (subsection "Rab8 activates while Rab10 inhibits cilia formation in A549 cells", first paragraph), but the data is not shown. At a minimum, this data should be shown.

We now include the requested data -- the effects are indeed seen in well ciliated cells such as RPEs and MEFs (new Figure 1C, Figure 5D, Figure 6C right).

> 2\) Neither the Rab8 or Rab10 T-to-E/A mutant proteins are functional and it seems likely that the mutant Rabs are non-functional independent of their presumed effects on phosphorylation, and this point is not adequately explored or clearly conveyed. It is shown that Rab10 T73A is cytosolic, explaining why it is non-functional. Why are the other rab8 and Rab10 mutants non-functional? Are they isoprenylated? If the mutants do not selectively affect phosphorylation (e.g. they alter isoprenylation), their use seems tangential to the main point of the paper.

As requested, we omitted our experiments using the mutant proteins since the results are not properly interpretable.

We have consolidated the mutant characterization data to a single place in the manuscript and include information on their binding or lack thereof to RILPL1 (Figure 2---figure supplement 1) and now add data on their in vitro prenylation (Figure 2C) and more fractionation (Figure 2B). This data is important to include for the field, as many studying phosphorylation rely on phosphomimetic mutants or non-phosphorylatable proteins without studying them in greater detail. We thank the reviewers for guiding us to this clearer means of presentation.

> 3\) The effect of the Rab10 LRRK2 phosphorylation site mutations (T73A, E) on its association with RILP1 should be determined, similar to the analysis of Rab8 mutants and RILP1 (Figure 3---figure supplement 1). This information is important for interpreting the phenotypes of the mutant proteins.

We now include this requested data, which belongs here, as the reviewers noted (Figure 2---figure supplement 1B).

> 4\) Please note that each of the reviewers were confused by certain aspects of the presentation (see the reviews). I encourage you to consider revising the presentation to address these sources of confusion.

We have re-organized the manuscript in response to each of the reviewer's comments.

> Separate reviews (please respond to each point):

Reviewer \#1:

> This study addresses the role of LRRK, a protein kinase implicated in Parkinson\'s disease, in ciliogenesis. Mutations in LRRK that cause PD activate its protein kinase activity, but how this leads to PD is unknown. The study follows an earlier publication that reported that Rab proteins are the principal substrates for LRRK, including Rab8 and Rab10, the focus of this study. Rab8 has previously been implicated in ciliogenesis, and the authors present evidence that phosphorylation of Rab8 by LRRK inhibits its function in ciliogenesis. In contrast, the authors find that depletion of Rab10, another Rab GTPase implicated in ciliogenesis, potentiates ciliogenesis and that phosphorylation of Rab10 by LRRK potentiates its inhibitory effect on ciliogenesis via enhanced interaction with RILPL1, a Rab10 effector of unknown function. It is shown that depletion of RILPL1 potentiates ciliogenesis, similar to depletion of Rab10. Finally, it is shown that PD mutations in LRRK cause a decrease in the proportion of ciliated cells and deficient SSH signaling in striatal cholinergic neurons of the mouse brain. The specific functions of Rab8 or Rab10 in ciliogenesis or PD are largely unknown. This is a technically sound, well controlled study, that clearly supports roles for Rab8 and Rab10 in ciliogenesis, though if these GTPases play direct, specific roles in ciliogenesis remains an open question. In my opinion, the major value of this study lies in the identification of functional consequences for LRRK-mediated phosphorylation of Rab8 and Rab10 in ciliogenesis, a finding that puts a spotlight on ciliogenesis for future studies of PD etiology.
>
> Phenotypic analyses of Rab8a/b knockout mice by Sato et al., 2014, showed essentially no effect on cilia number and little evidence of ciliopathies that would be expected by the loss of a key factor in ciliogenesis. Moreover, they reported that knockout of Rab10 resulted in a loss of cilia, the opposite reported here. How do the authors reconcile these published observations with their results? If I understand correctly, the authors propose that Rab8 \"activates\" ciliogenesis, rather than provides an essential role, but it is unclear to me what \"activate\" means.

We removed the word activate and replaced it with increases.

Sato et al. reported no change in cilia number of length upon Rab8A/Rab8B knockout, and additional Rab10 siRNA decreases ciliation 15%. These authors never show the effect of Rab10 KO alone in their wild type background -- it is always in the background of double knockout. It is possible that the loss of Rab8B or the double knockdown of Rab10 and Rab13 explains the differences from what we observe and their findings and we have tried to clarify the text in the Discussion.

> It is shown that loss of RILPL1 potentiates ciliogenesis, similar to loss of Rab10. It is also shown that Rab10 does not require RILPL1 for its effects on ciliogenesis (\"This suggests that Rab8A and Rab10 do not require RILPL1 for their effects on ciliogenesis...\"). So why are Rab10 and RILPL1 proposed (\"LRRK2 kinase acts via a pRab10-RILPL1 pathway to inhibit ciliogenesis\") to function on the same ciliogenesis pathway? It would be helpful if the authors clarified this conclusion.

We have clarified the text -- "Figure 6D compares two scenarios by which Rab10 and RILPL1 interfere with cilia formation. At endogenous levels of expression, we propose that LRRK2 generates an inhibitory complex that contains pRab10 and RILPL1. RILPL1 shows enhanced binding to p-Rab10, and our data show that LRRK2 inhibition requires both of these proteins to yield a ciliation defect. In addition, in the absence of LRRK2, upon overexpression of RILPL1, we also detect inhibition of cilia formation; this inhibition requires the presence of Rab10, and may reflect a similar inhibitor complex that requires overexpression to generate in the absence of Rab10 phosphorylation. On the other hand, overexpressed Rab10 can also inhibit cilia formation in a RILPL1-independent manner, that may involve RILPL2 or other proteins. Further work is needed to explore this possibility."

> Additional data files and statistical comments:
>
> Rigour and extent of the statistical information are satisfactory.

Reviewer \#2:

> \[...\] The negative regulation of ciliogenesis by Rab10/RILPL1 is an interesting finding that, if generalizable to other cell types/tissues, represents a novel insight into ciliogenesis that motivates future analysis of the underlying mechanism. Additionally, the findings that LRRK2 hyper-activity inhibits ciliogenesis and blunts Hedgehog signaling provide further evidence that ciliary defects may contribute to Parkinson\'s Disease. Lastly, the observation that Rab10 knockdown suppresses ciliogenesis defects seen in MEFs with elevated LRRK2 activity provides an important connection between the two aforementioned findings. As detailed below, the study could be strengthened by further examining Rab10\'s role in ciliogenesis in cell lines that are more commonly used to study cilia. Additionally, some data are presented in a confusing manner and do not support some of the conclusions reached. These unclear sections significantly obscure the key results and should be revised before publication in eLife.
>
> 1\) Many of the experiments are done in A549 cells, but A549 cells ciliate at a relatively low rate (\~25%) and are not commonly used to study ciliogenesis. Thus, it is possible that the inhibitory effects on ciliogenesis of Rab10/RILPL1 may be a distinct feature of this cell type rather than indicative of a more general role for these proteins in regulating cilium formation (especially as Sato et al., 2014, reported Rab10 to be instead a positive regulator of ciliogenesis that acts redundantly with Rab8A and Rab8B). This concern is partially mitigated by the data from LRRK2-R1441G MEFs shown in Figure 6, but it would nonetheless be helpful to repeat a limited number of key experiments in RPE cells or wildtype MEFs (e.g. to show that Rab10/RILPL1 can inhibit ciliogenesis in these cells). In the first paragraph of the subsection "Rab8 activates while Rab10 inhibits cilia formation in A549 cells", the authors note that cilia were examined in RPE cells following knockdown of Rab8A and Rab10, but the data are not shown.

We agree and include now data in other cell types that were only omitted for space reasons. Also, note that in professional ciliated cells like RPE, one cannot as easily detect a stimulation of ciliation since most cells start ciliated. As above, we include the data -- the effects are indeed seen in well ciliated cells such as RPEs and wt MEFs (new Figure 1C, Figure 5D, Figure 6C right).

> 2\) Several sections of the Results are confusing and should be revised (see Minor Comments 1-5 for details).
>
> 3\) While the authors have tested the functional interdependencies among LRRK2, Rab8A, Rab10, and RILPL1, the bigger picture of how these proteins interact to control ciliogenesis remains unclear with respect to where Rab8A fits in. Could the authors integrate Rab8A into a pathway model like that in Figure 6D? It seems that one possible model is RILPL1 \--\| Rab8A \--\| Rab10 \--\| ciliogenesis, with LRRK2 promoting Rab10 activity, but this diverges a bit from Figure 6D and perhaps there are alternatives that fit better or otherwise merit consideration. Lastly, given the evidence that Rab10 can inhibit ciliogenesis in the absence of RILPL1, are there Rab10 effectors that the authors view as good candidates for mediating Rab10\'s inhibition of ciliogenesis?

We added a new experiment (Figure 1G) that shows that Rab8A can still increase ciliation in the absence of Rab10. We thus cannot yet place it in our pathway. As for other effectors, RILPL2 is obvious (Steger et al., 2017) but this is beyond the scope of this paper.

> Minor Comments:
>
> 1\) The authors state, \"addition of exogenous Rab10 suppresses cilia formation in cells lacking Rab8A or Rab10. Moreover, Rab8A enhances cilia formation in cells lacking Rab10; thus this represents an independent pathway for ciliogenesis activation\". First, the effect of exogenous Rab10 expression on ciliogenesis in Rab8A-deficient cells does not appear to have been examined here.

Thank you for catching this error! We corrected the text as follows: "Thus, Rab10 is a dominant suppressor of cilia formation. Moreover, endogenous Rab8A enhances cilia formation in cells lacking Rab10 (from \~25% ciliation to \~50% ciliation); in addition, exogenous Rab8A even further increases ciliation in the cells lacking Rab10 protein (Figure 1F). Thus, Rab8A drives a Rab10 independent pathway for cilia formation."

> Second, the data indicate that Rab8A does not enhance cilium formation in cells lacking Rab10; rather, Figure 2B shows that cells lacking Rab10 bypass Rab8A\'s normal role in promoting ciliogenesis -- itself a striking finding.

This is now Figure 1F. It shows that loss of Rab10 in a Rab8A KO gives enhanced cilia formation without either Rab---cilia formation is not always Rab8A dependent. Rab8A pathway can act on top of this to enhance cilia formation (new Figure 1G).

> Finally, this section concludes by discussing evidence from Sato et al. that Rab8A/B double-mutant mice show normal primary cilia. This fact seems to confuse or contradict the present data; it may be helpful instead to discuss the findings of Sato et al., 2014, in the Discussion.

Good suggestion, we moved this to the Discussion.

> 2\) The conclusions that can be drawn from the use of phospho-site T-\>A and T-\>E mutants are also not clear. As the authors note, the Rab10A T73A appears to be non-functional and should not be used as a phosphorylation-blocking allele. Given that Rab8A T72A and T72E mutants both fail to rescue ciliogenesis defects in Rab8A knockout cells and interact poorly with RILPL1 (while phosphorylated Rab8A robustly binds RILPL1), it is likely these mutants are non-functional and do not specifically block or mimic phosphorylation. Thus, the statement in the Abstract that \"Rab8A phosphorylation blocks its ability to promote ciliogenesis\" should be revised.

Point taken.

> Also, is the more potent inhibition of ciliogenesis by the Rab10 T73E mutant relative to wildtype Rab10 statistically significant?

Yes but we removed the data from the paper because the mutants are nonfunctional.

> 3\) The order of data presented in the text does not closely follow the order of data in the figures, especially for the first 2 figures and Figure 3---figure supplement 1. Adjusting the order of the figure panels would make the paper easier to follow. Also, in the first paragraph of the subsection "RILPL1 regulates pRab10 localization", the reference to Figure 3---figure supplement 1 appears to instead refer to Figure 5---figure supplement 1. In the first paragraph of the subsection "RILPL1 regulates pRab10 localization", the reference to Figure 4B appears to refer instead to Figure 4A. Lastly, what is being shown in Figure 2A with respect to GFP-Rab8 and GFP-Rab10?

We have fixed this problem as requested.

> 4\) An additional area of confusion is in the section titled, \"RILPL1 suppresses cilia formation via centrioles\". It seems from the data in Figure 5F-H that, contrary to the section title, RILPL1 suppresses cilia formation independently of effects on centriole spacing. Additionally, while the effects on ciliogenesis of RILPL1 expression in RILPL1 KO cells are striking, it would be informative to assess whether a similar inhibition of ciliogenesis occurs when RILPL1 is over-expressed in wildtype cells.

We have added the requested data and changed the heading and moved the centrosome cohesion to Figure 5---figure supplement 1 and omitted it from the Discussion.

> 5\) In Figure 4, the authors analyze the effects of RILPL1 fragments on pRab10 localization. While the reported effects are interesting, the suggestion \"that the RILPL1 N-terminus interacts with pRab10 in pericentriolar membranes\" should perhaps be tempered given that a prior report from these groups showed that it is the C-terminal RH domain in RILPL1 that mediates interaction with Rab8A (PMID: 29125462), and the same may be true for Rab10 (even considering the data shown).

Unfortunately the mutants reported in those experiments were later found to be mislocalized to the nucleus so may have lost binding capacity for the wrong reason.

> 6\) The results from LRRK2-G2019S iPS cells in Figure 7C-E could be attributed to differences in ciliogenesis associated with the process of deriving the mutant versus wildtype lines. This potential concern could be alleviated by examining whether MLi2 treatment restores normal levels of cilium formation to the G2019S cells.

We agree and as requested we have now added the MLi2 control, which confirms our earlier conclusions (new Figure 7C).

> 7\) The authors state that \"Yoshimura et al., 2007, were the first to show that Rab8A, but not Rab8B, is the only Rab GTPase to localize to primary cilia in hTert-RPE1 cells\". This statement may be misleading to some readers given subsequent evidence that GFP-Rab23 localizes to RPE1 cilia (PMID: 26136363), as does Rab8B (PMID: 21273506). Additionally, while Rab8 and Rabin8 promote ciliogenesis, this effect appears to be only partly through the BBSome and may instead be primarily related to delivery of membrane vesicles to the growing cilium (e.g. PMID: 25812525).

Text revised as suggested.

Reviewer \#3:

> This paper evaluates the role of the Rab8 and Rab10 GTPases as well as the Rab effector RILPL1 in the regulation of ciliogenesis by the LRRK2 kinase. It then goes on to explore the role of changes in ciliogenesis in mediating the effects of LRRK2 in Parkinsons disease. In general the studies are well designed and well executed and the results are by in large convincing. While the paper probably opens as many questions as it closes, it represents an important advance in understanding one molecular mechanism underlying a genetic cause of Parkinsons and should have a broad audience. Below I have outlined a number of points that should be explored more thoroughly or, in one case, deleted for clarity.
>
> 1\) In Figure 1D and E what is the level of expression of Rab8 and 10 and their mutant alleles relative to the endogenous level? It looks very high.

We omitted the mutant alleles because the proteins are nonfunctional; in A549 rescue experiments, the Rabs are expressed 4X (Rab10) or 10 fold (Rab8A) over endogenous (now added to the subsection "Rab8A increases while Rab10 inhibits cilia formation in A549 cells", first paragraph).

> 2\) The relationship of Rab8 to Rab10 has not been explored in depth. Does the loss or overexpression of one affect the localization of the other at the cilia? Does the loss or overexpression of one affect the activation of the other? They are closely related and can both bind RILPL, how does each affect the interaction of the other with this common effector? They interpret their data to indicate that the effects of each on ciliogenesis are totally independent of the other, but I am not so sure.

Rab8 goes to the cilium fine in Rab10KO cells. We cannot say if Rab10 is localized at the base of the cilium in Rab8A KO cells as they are only poorly ciliated. The levels of each protein are unchanged upon KO of the other Rab (Figure 1---figure supplement 1). We added this in the last paragraph of the subsection "Rab8A increases while Rab10 inhibits cilia formation in A549 cells".

> 3\) In Figure 2B, C and D a WT control is needed.

Included as requested in what is now Figure 1G.

> 4\) The text refers to cells in which a component is knocked out by CRISPR as \"depleted\". It would be more accurate to say that the component is deleted. Depletion suggests a partial loss.

Fixed as requested throughout.

> 5\) In Figure 2E they should also test the membrane association of the Rab8 mutants. Directly testing for isoprenylation of the various Rab8 and 10 alleles would address the issue more clearly.

Done as requested (new Figure 2B, C; mutants omitted).

> 6\) Figure 3---figure supplement 1 looks at the effect of phosphorylation on the interaction of Rab8 with RILPL, however the effects on ciliogenesis are predominantly mediated by Rab10. They should also explore the effects of phosphorylation of Rab10 on its interaction with RILPL.

We have now added this as requested (Figure 2---figure supplement 1B).

> 7\) The discussion of the effects of RILPL on centriolar distance is very confusing and appears to be of no obvious relevance to this story. In Figure 5G and H it looks like there is an effect, but in 5I it looks like there isn\'t a significant effect. This is confusing. I would suggest deletion of this section of the paper as it distracts from the main line of reasoning.

The group of Sabine Hilfiker published that she believes LRRK2 interferes with centrosomal cohesion, which is why we have included this data. We moved it to Figure 5---figure supplement 1 so that it does not detract from the current story, and we no longer discuss it in the Discussion.

We thank the reviewers for their very thoughtful and careful evaluations!

[^1]: These authors contributed equally to this work.
